ADP-A2M4CD8 as Monotherapy or in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in
subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.
Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric,
head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.